Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the frequency of continuous glucose monitoring (CGM) device use, factors associated with its use, and the relationship of CGM with diabetes outcomes (HbA1c, severe hypoglycemia [SH], and diabetic ketoacidosis [DKA]). RESEARCH DESIGN AND METHODS: Survey questions related to CGM device use 1 year after enrollment in the T1D Exchange clinic registry were completed by 17,317 participants. Participants were defined as CGM users if they indicated using real-time CGM during the prior 30 days. RESULTS: Nine percent of participants used CGM (6% of children <13 years old, 4% of adolescents 13 to <18 years, 6% of young adults 18 to <26 years, and 21% of adults ≥26 years). CGM use was more likely with higher education, higher household income, private health insurance, longer duration of diabetes, and use of insulin pump (P < 0.01 all factors). CGM use was associated with lower HbA1c in children (8.3% vs. 8.6%, P < 0.001) and adults (7.7% vs. 7.9%, P < 0.001). In adults, more frequent use of CGM (≥6 days/week) was associated with lower mean HbA1c. Only 27% of users downloaded data from their device at least once per month, and ≤15% of users reported downloading their device at least weekly. Among participants who used CGM at baseline, 41% had discontinued within 1 year. CONCLUSIONS: CGM use is uncommon but associated with lower HbA1c in some age-groups, especially when used more frequently. Factors associated with discontinuation and infrequent use of retrospective analysis of CGM data should be considered in developing next-generation devices and education on CGM use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such phenomena question the accuracy and credibility of CGM and make patients less reactive to alarms and less willing to retain them activated or even continue to use CGM [ 43 , 55 ].”
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Klonoff, D. C. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1231 · Cited by 724
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 1×
“occasional) use of CGM is associated with better glycemic control, as measured by HbA1c (5,8), leading to a practice guideline recommending CGM for adults who are able to use it at least 6 days a week (9).”
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
Battelino, T., Phillip, M., Bratina, N., Nimri, R., Oskarsson, P., & Bolinder, J. (2011) · Diabetes Care · doi:10.2337/dc10-1989 · Cited by 490
The T1D exchange clinic registry
Beck, R. W., Tamborlane, W. V., Bergenstal, R. M., Miller, K. M., DuBose, S. N., Hall, C. A., & for the T1D Exchange Clinic Network (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1561 · Cited by 456
Self-citationThe effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Effectiveness of Continuous Glucose Monitoring in a Clinical Care Environment
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1502 · Cited by 313
Cited by
Items 101–200 of 338
Weinstock, R. S., Schütz-Fuhrmann, I., Connor, C. G., Hermann, J. M., Maahs, D. M., Schütt, M., Agarwal, S., Hofer, S. E., Beck, R. W., & Holl, R. W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.024 · Cited by 52
Self-citationType 1 diabetes mellitus management in young children: implementation of current technologies
Nevo-Shenker, M., Phillip, M., Nimri, R., & Shalitin, S. (2019) · Pediatric Research · doi:10.1038/s41390-019-0665-4 · Cited by 52
Landau, Z., Abiri, S., Gruber, N., Levy-Shraga, Y., Brener, A., Lebenthal, Y., Barash, G., Pinhas-Hamiel, O., & Rachmiel, M. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1218-8 · Cited by 48
Avari, P., Reddy, M., & Oliver, N. (2020) · Diabetic Medicine · doi:10.1111/dme.13942 · Cited by 44
Al Hayek, A. A., Robert, A. A., & Al Dawish, M. A. (2019) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551419861102 · Cited by 44
Everett, E. M., & Wisk, L. E. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211050649 · Cited by 47
Shao, J., Liu, Z., Li, S., Feng, H., Li, J., Nie, Z., Pan, Y., Feng, H., Li, Y., Yang, L., et al. (2024) · JMIR Medical Informatics · doi:10.2196/56909 · Cited by 47
“With the sacrifice of high specificity, false alarms became an obstacle for the safe and widespread use of CGM devices [45-47].”
BackgroundClements, M. A., & Staggs, V. S. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817691302 · Cited by 42
Deiss, D., Irace, C., Carlson, G., Tweden, K. S., & Kaufman, F. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0159 · Cited by 44
Limitations of Continuous Glucose Monitor Usage
Anhalt, H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0011 · Cited by 39
“Not surprisingly they also found that patients could maximize their benefit by wearing the devices more frequently and using them in real time.(21) No discussion about limitations to usage of diabetes devices is complete without addressing the lack of adoption due to poor reimbursement.”
Prahalad, P., Addala, A., Buckingham, B. A., Wilson, D. M., & Maahs, D. M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0204 · Cited by 40
Self-citationDovč, K., Cargnelutti, K., Sturm, A., Šelb, J., Bratina, N., & Battelino, T. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.005 · Cited by 42
Burckhardt, M.-A., Abraham, M. B., Mountain, J., Coenen, D., Paniora, J., Clapin, H., Jones, T. W., & Davis, E. A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0149 · Cited by 36
“Real-life outcomes have been explored in observational studies, 15 and national and international registries 16,17 and provide an important platform to monitor the reimbursement program.”
Smith, M. B., Albanese-O’Neill, A., Macieira, T. G. R., Yao, Y., Abbatematteo, J. M., Lyon, D., Wilkie, D. J., Haller, M. J., & Keenan, G. M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0136 · Cited by 41
“1 Significant age-related trends are observed when evaluating the uptake and consistent use of CGM. Adolescents and young adults have the lowest rates of uptake 7,8 and consistency of use.”
Everett, E. M., Wright, D. R., Williams, A. H., Divers, J., Pihoker, C., Liese, A. D., Bellatorre, A., Kahkoska, A. R., Bell, R. A., Mendoza, J. A., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0340 · Cited by 41
Aronson, R., Abitbol, A., & Tweden, K. S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13726 · Cited by 41
Intermittent Use of Continuous Glucose Monitoring: Expanding the Clinical Value of CGM
Ziegler, R., Heinemann, L., Freckmann, G., Schnell, O., Hinzmann, R., & Kulzer, B. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820905577 · Cited by 39
Piona, C., Dovc, K., Mutlu, G. Y., Grad, K., Gregorc, P., Battelino, T., & Bratina, N. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12729 · Cited by 34
Mencher, S., WEINZIMER, S. A., Nally, L. M., Name, M. A. V., Nuñez-Smith, M., & Sadler, L. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0413 · Cited by 37
“15 However, contrary to our findings, providers in that study were seen as barriers to device uptake due to a lack of shared decision-making.”
Putman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T., Stecenko, A. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0380 · Cited by 35
Boscari, F., Vettoretti, M., Cavallin, F., Amato, A. M. L., Uliana, A., Vallone, V., Avogaro, A., Facchinetti, A., & Bruttomesso, D. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01624-2 · Cited by 33
Transdermal amperometric biosensors for continuous glucose monitoring in diabetes
Liu, Y., Li, Y., & Cui, Y. (2022) · Talanta · doi:10.1016/j.talanta.2022.124033 · Cited by 33
Afandi, B. O., Hassanein, M. M., Roubi, S., & Nagelkerke, N. J. D. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.036 · Cited by 33
Reeve, C., Cummings, E. A., McLaughlin, E. N., Smith, S., & Gadbois, S. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.04.020 · Cited by 33
Volčanšek, Š., Lunder, M., & Janež, A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0131 · Cited by 33
“Real-time continuous glucose monitoring (rt-CGM) has been shown to optimize glycemic control in T1D patients 15–19 by creating continuous snapshots of patients’ glycemia, acknowledging excursions and predicting patterns that offer safety advantages.”
Pilot Study of a Novel Application for Data Visualization in Type 1 Diabetes
Wong, J. C., Neinstein, A. B., Look, H., Arbiter, B., Chokr, N., Ross, C., & Adi, S. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817691305 · Cited by 32
Self-citationYingling, L., Allen, N. A., Litchman, M. L., Colicchio, V. D., & Gibson, B. (2019) · JMIR Diabetes · doi:10.2196/12936 · Cited by 32
Wallia, A., Umpierrez, G. E., Nasraway, S. A., Klonoff, D. C., on behalf of PRIDE Investigators, Alexanian, S., Cagliero, E., Cook, C. B., Draznin, B., Drincic, A., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816656380 · Cited by 29
Bianchi, C., Aragona, M., Rodia, C., Baronti, W., Gennaro, G., Bertolotto, A., & Prato, S. D. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.10.012 · Cited by 31
Been, R. A., Lameijer, A., Gans, R. O. B., van Beek, A. P., Kingsnorth, A. P., Choudhary, P., & van Dijk, P. R. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241236289 · Cited by 31
“…between income, which is closely related to occupational status, and CGM use has often been reported, from the introduction of CGM devices, 56 to the present day, 58 in which those in high-income groups ( > $100.000 annually) are twice as likely to use a CGM than those in low-income…”
BackgroundInfluentialSalient Characteristics of Youth with Type 1 Diabetes Initiating Continuous Glucose Monitoring
Teló, G. H., Volkening, L. K., Butler, D. A., & Laffel, L. M. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0290 · Cited by 31
Technology use in transition-age patients with type 1 diabetes: reality and promises
Los, E., Ulrich, J., & Guttmann-Bauman, I. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816632543 · Cited by 28
Hansen, E. A., Klee, P., Dirlewanger, M., Bouthors, T., Elowe-Gruau, É., Stoppa‐Vaucher, S., Phan-Hug, F., Antoniou, M.-C., Pasquier, J., Dwyer, A. A., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12723 · Cited by 31
Marks, B. E., Wolfsdorf, J. I., Waldman, G., Stafford, D. E. J., & Garvey, K. C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0331 · Cited by 31
Dril, E. V., & Schumacher, C. (2019) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1088 · Cited by 31
Walsh, J. S. A., Roberts, R., Weber, D., Faber-Heinemann, G., & Heinemann, L. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815588945 · Cited by 30
“1) (1-10) days, with longer use in the US than in GER (3.”
BackgroundClinical Use of Continuous Glucose Monitoring in Pediatrics
Lal, R., & Maahs, D. M. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0013 · Cited by 31
Self-citationYu, S., Varughese, B., Li, Z., & Kushner, P. R. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0435 · Cited by 30
Rasbach, L. E., Volkening, L. K., Markowitz, J. T., Butler, D. A., Katz, M. L., & Laffel, L. M. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0366 · Cited by 30
Use of Diabetes Technology in Children
Desrochers, H. R., Schultz, A. T., & Laffel, L. M. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.11.001 · Cited by 29
Pediatric Medicaid Patients With Type 1 Diabetes Benefit From Continuous Glucose Monitor Technology
Ravi, S., Coakley, A., Vigers, T., Pyle, L. L., Forlenza, G. P., & Alonso, T. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820906214 · Cited by 29
Tsuji, S., Ishikawa, T., Morii, Y., Zhang, H., Suzuki, T., Tanikawa, T., Nakaya, J., & Ogasawara, K. (2020) · Journal of Medical Internet Research · doi:10.2196/16053 · Cited by 29
Introducing a Remote Patient Monitoring Usability Impact Model to Overcome Challenges
Baumann, S., Stone, R., & Abdelall, E. S. (2024) · Sensors · doi:10.3390/s24123977 · Cited by 28
“Berg et al. [83] reported that 35% of continuous glucose monitoring users developed skin lesions, and Wong et al. [84] found that nearly half of all users discontinued use due to discomfort and skin reactions.”
BackgroundHuhn, F., Lange, K., Jördening, M., & Ernst, G. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221081216 · Cited by 28
The rise of technology in diabetes care. Not all that is new is necessarily better
Acerini, C. L. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12366 · Cited by 28
“As a result, many patients starting or transferring to CSII or CGM fail to optimize their diabetes control beyond that achieved with cheaper conventional treatment regimens, or are unable to sustain initial improvements over the longer term (27, 42).”
BackgroundAcceptability of Implantable Continuous Glucose Monitoring Sensor
Barnard, K. D., Kropff, J., Choudhary, P., Neupane, S., Bain, S. C., Kapitza, C., Forst, T. M., Link, M., MDINGI, C., & DeVries, J. H. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817735123 · Cited by 28
Zavitsanou, S., MASSA, J. S., Deshpande, S., Pinsker, J. E., Church, M. M., ANDRE, C. C., Doyle, F. J., Michelson, A., Creason, J., Dassau, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0109 · Cited by 28
Weinstock, R. S., Prahalad, P., Rioles, N. A., & Ebekozien, O. A. (2021) · Clinical Diabetes · doi:10.2337/cd21-0032 · Cited by 27
Sørgård, B., Iversen, M. M., & Mårtensson, J. (2019) · Journal of Clinical Nursing · doi:10.1111/jocn.14911 · Cited by 27
Type 1 Diabetes Care in Mexico: An Analysis of the RENACED-DT1 National Registry
Faradji, R. N., Valenzuela-Lara, M., Menchaca, A. P. D.-B., Almeda‐Valdés, P., Antonio‐Villa, N. E., Vidrio-Velázquez, M., Islas-Ortega, L., Ramos-Méndez, A. M., la Garza-Hernández, N. E. D., Bustamante-Martínez, J. F., et al. (2021) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.20000498 · Cited by 26
GlucoMine: A Case for Improving the Use of Wearable Device Data in Diabetes Management
Bartolome, A., Shah, S., & Prioleau, T. (2021) · Proceedings of the ACM on Interactive Mobile Wearable and Ubiquitous Technologies · doi:10.1145/3478109 · Cited by 25
“For example, research shows that less than 30% of patients with diabetes routinely review and reflect on their historical CGM data to learn from it and inform their management strategy [68, 69].”
BackgroundAljawarneh, Y. M., Wood, G. L., Wardell, D. W., & Al-Jarrah, M. D. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.04.003 · Cited by 25
Massa, G., Gys, I., Bevilacqua, E., Wijnands, A., & Zeevaert, R. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.015 · Cited by 24
Dadlani, V., Kaur, R. J., Stegall, M. D., Xyda, S., Kumari, K., Bonner, K., Smith, B. H., Thapa, P. B., Dean, P. G., & Kudva, Y. C. (2019) · Clinical Transplantation · doi:10.1111/ctr.13719 · Cited by 24
Hispanic Caregivers' experience of pediatric type 1 diabetes: A qualitative study
Tremblay, E. S., Ruiz, J., Dykeman, B., Maldonado, M., & Garvey, K. C. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13247 · Cited by 24
Impact of new technologies on diabetes care
Giani, E., Scaramuzza, A. E., & Zuccotti, G. V. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.999 · Cited by 24
Youth Involvement in the Decision to Start CGM Predicts Subsequent CGM Use
Miller, V. A., Xiao, R., Slick, N., Feudtner, C., & Willi, S. M. (2020) · Diabetes Care · doi:10.2337/dc20-0348 · Cited by 23
Rai, S., Hulse, A., & Kumar, P. K. M. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.192894 · Cited by 23
Ottosson, A. B., Åkesson, K., Ilvered, R., Forsander, G., & Särnblad, S. (2017) · Acta Paediatrica · doi:10.1111/apa.13949 · Cited by 23
Perceptions of Diabetes Technology Use in Cystic Fibrosis-Related Diabetes Management
Marks, B. E., Kilberg, M. J., Aliaj, E., Fredkin, K., Hudson, J., Riva, D., Roman, C., Kelly, A. T., & Putman, M. S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0201 · Cited by 23
“10,11,21 Although not previously documented in the T1D population, we also identified increased worry about blood glucose as another reason for discontinuation in this CFRD population.”
Ridder, F. D., den Brinker, M., & Block, C. E. M. D. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865399 · Cited by 23
Beyond A1C: exploring continuous glucose monitoring metrics in managing diabetes
Friedman, J. G., Coyne, K., Aleppo, G., & Szmuilowicz, E. D. (2023) · Endocrine Connections · doi:10.1530/ec-23-0085 · Cited by 22
Self-citationHirsch, I. B., & Verderese, C. A. (2017) · Endocrine Practice · doi:10.4158/ep171962.ra · Cited by 22
Self-citationPutman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T. C., Stecenko, A. A., et al. (2023) · Diabetes · doi:10.2337/db22-0949 · Cited by 22
Forlenza, G. P., Pyle, L. L., Maahs, D. M., & Dunn, T. C. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12474 · Cited by 22
Self-citationUse of Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes
Chan, C. L. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0905-0 · Cited by 22
Nefs, G., Bazelmans, E., Marsman, D. E., Snellen, N., Tack, C. J., & de Galan, B. E. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107910 · Cited by 22
McGill, D. E., Volkening, L. K., Butler, D. A., Harrington, K. R., Katz, M. L., & Laffel, L. M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0037 · Cited by 22
Weight Management in Youth with Type 1 Diabetes and Obesity: Challenges and Possible Solutions
Zaharieva, D. P., Addala, A., Simmons, K. M., & Maahs, D. M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00411-z · Cited by 21
Self-citationDiabetology 4.0: Scoping Review of Novel Insights and Possibilities Offered by Digitalization
Eberle, C., Stichling, S., & Löhnert, M. (2021) · Journal of Medical Internet Research · doi:10.2196/23475 · Cited by 21
“Reasons for discontinuation include discomfort when wearing the CGM system, problems with inserting the sensor, or with the adhesive holding the sensor on the skin [28].”
Thompson, B., Leighton, M. E., Korytkowski, M. T., & Cook, C. B. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1056-7 · Cited by 21
Sherrill, C. H., Lee, S., & Bradley, C. L. (2021) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2021.11.021 · Cited by 20
Continuous glucose monitoring: a systematic review of sensor systems and prospects
Ray, P. P. (2018) · Sensor Review · doi:10.1108/sr-12-2017-0268 · Cited by 20
Ritholz, M. D., Henn, O., Atakov-Castillo, A., Wolpert, H. A., Edwards, S., Fisher, L., & Toschi, E. (2019) · JMIR Diabetes · doi:10.2196/14032 · Cited by 20
Price, D. A., & Walker, T. C. (2016) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2016.12.01.24 · Cited by 20
Luk, A. O. Y., Fan, Y., Fan, B., Chow, E. W. K., & Tony, C. K. O. (2025) · Diabetologia · doi:10.1007/s00125-025-06482-8 · Cited by 19
“The under-use of diabetes technologies among minority ethnic groups, such as continuous glucose monitoring and insulin pumps and intensive insulin regimens, has been well documented [211, 213].”
Shapira, A., Volkening, L. K., Borus, J. S., & Laffel, L. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035451 · Cited by 19
Deeb, A., Yousef, H., Qahtani, N. A., Artan, I., Suliman, S., Tomy, M., Abdulrahman, L., Suwaidi, H. A., Attia, S., & Nagelkerke, N. J. D. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0351-9 · Cited by 19
Review of Community-Engaged Research in Pediatric Diabetes
Butler, A. M., Hilliard, M. E., & Comer-HaGans, D. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1029-x · Cited by 19
Ekhlaspour, L., Tabatabai, I., & Buckingham, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819851790 · Cited by 17
Berg, A. K., Thorsen, S. U., Thyssen, J. P., Zachariae, C. O. C., Keiding, H., & Svensson, J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0368 · Cited by 19
“Because insulin pumps and glucose sensors decrease glycated hemoglobin (HbA1c) levels and, therefore, the risk of long-term complications, 26 discontinuing device use due to skin problems 27,28 may increase the cost of diabetes treatment indirectly by increasing the risk of long-term complications,…”
Design Considerations for Artificial Pancreas Pivotal Studies
Russell, S. J., & Beck, R. W. (2015) · Diabetes Care · doi:10.2337/dc15-2449 · Cited by 18
Self-citationWinterdijk, P., Aanstoot, H., & Nefs, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110886 · Cited by 17
Kempegowda, P., Chandan, J. S., Coombs, B., de Bray, A., Jawahar, N., James, S., Ghosh, S., & Narendran, P. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000695 · Cited by 18
Puhr, S., Calhoun, P. M., Welsh, J. B., & Walker, T. C. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0134 · Cited by 17
“15 Similarly, SMBG testing frequency was lower for participants during rtCGM use in CGM outcome trials even though trial participants were instructed to use rtCGM adjunctively.”
Glycemic Status Assessment by the Latest Glucose Monitoring Technologies
Malandrucco, I., Russo, B., Picconi, F., Menduni, M., & Frontoni, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218243 · Cited by 17
Diabetes Device Interoperability for Improved Diabetes Management
Silk, A. D. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815595051 · Cited by 15
“In contemporary diabetes management strategies, glucose meters are often used with additional electronic diabetes devices (an insulin pump, CGM) to provide significant health benefits.(2,3) However, in some cases, the burden of managing multiple devices may contribute to patients choosing not to adopt new technologies.”
BackgroundRole of Continuous Glucose Monitoring in Insulin-Requiring Patients with Diabetes
Welsh, J. B. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0100 · Cited by 17
“Clinical inertia in primary care settings, 51 out-of-pocket costs, and the perceived need for extensive specialized training remain barriers to wider adoption of CGM.”
InfluentialCutaneous adverse events related to FreeStyle Libre device – Authors' reply
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P. H. L. M., Kröger, J., & Weitgasser, R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30893-0 · Cited by 17
Tremblay, E. S., Bernique, A. S., Garvey, K., & Astley, C. M. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231183985 · Cited by 16
“35 Early studies in CGM efficacy highlighted the importance of sustained sensor use, 1,3,6,14,36 which our findings suggest may be more difficult for vulnerable populations to achieve.”
Chen, H., Lai, Y., & Jiang, Y. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70019 · Cited by 16
“These challenges remain unresolved and require further attention 17 .”
Pease, A., Szwarcbard, N., Earnest, A., Andrikopoulos, S., Wischer, N., & Zoungas, S. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108609 · Cited by 16
The Impact of Technology on Current Diabetes Management
Garvey, K. C., & Wolfsdorf, J. I. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.04.005 · Cited by 16
Diabetes Complications in Childhood Diabetes: New Biomarkers and Technologies
Bjornstad, P., & Maahs, D. M. (2015) · Current Pediatrics Reports · doi:10.1007/s40124-015-0081-0 · Cited by 16
“AlthoughCGMuse is currently low, it is associated with lower HbA1c in some agegroups, especially when used more frequently [112].”
BackgroundSelf-citationHochfellner, D. A., Simic, A., Taucher, M. T., Sailer, L. S., Kopanz, J., Pöttler, T., & Mader, J. K. (2022) · Biosensors · doi:10.3390/bios12020106 · Cited by 15
Institutional role conflict in the digital age: The case of diabetes management at school
Puckett, C., Wong, J. C., Talbot, S., Min, H. J., & Chokr, N. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100215 · Cited by 15
“Studies show numerous benefits: pumps and CGM can improve glycemic control, reduce hypoglycemia, and reduce diabetes burden when used regularly (Pańkowska et al., 2009; Pickup & Sutton, 2008; Tamborlane et al., 2008; Wong et al., 2014).”
BackgroundSelf-citationUsing Flash Continuous Glucose Monitoring in Primary Practice
Hirsch, I. B., & Wright, E. E. (2018) · Clinical Diabetes · doi:10.2337/cd18-0054 · Cited by 15
Self-citationSmith, M. B., Albanese-O’Neill, A., Yao, Y., Wilkie, D. J., Haller, M. J., & Keenan, G. M. (2020) · JMIR Diabetes · doi:10.2196/15410 · Cited by 15
Schwartz, D. D., Banuelos, R. C., Uysal, S., Vakharia, M., Hendrix, K. R., Fegan‐Bohm, K., Lyons, S. K., Sonabend, R., Gunn, S., & Dei-Tutu, S. A. (2022) · Clinical Diabetes · doi:10.2337/cd21-0070 · Cited by 15
Contact dermatitis in children caused by diabetes devices
da Silva, C. A., Bregnhøj, A., Mowitz, M., Bruze, M., Andersen, K. E., & Sommerlund, M. (2022) · Contact Dermatitis · doi:10.1111/cod.14166 · Cited by 15
Metadata
- Authors
- Wong, J. C., Foster, N. C., Maahs, D. M., Raghinaru, D., Bergenstal, R. M., Ahmann, A. J., Peters, A. L., Bode, B. W., Aleppo, G., Hirsch, I. B., Kleis, L., Chase, H. P., DuBose, S. N., Miller, K. M., Beck, R. W., Adi, S., & for the T1D Exchange Clinic Network
- Affiliations
- University of California, San Francisco (US)
- Jaeb Center for Health Research (US)
- University of Colorado Denver (US)
- Park Nicollet Health Services (US)
- Oregon Health & Science University (US)
- University of Southern California (US)
- Atlanta Diabetes Associates (US)
- Northwestern University (US)
- University of Washington (US)
- Spectrum Health (US)
- Corresponding author
- Miller, Kellee M.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-10
- Volume
- 37
- Issue
- 10
- Pages
- 2702-2709
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4392936
- OpenAlex
- W2136450455
- Semantic Scholar
- a3013d7ae63769a7d02f5f5ea02fd388f34dfe01
- Cited by
- 318
- References
- 19
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 15 · 2023: 19 · 2022: 20 · 2021: 27 · 2020: 33 · 2019: 38 · 2018: 45 · 2017: 35 · 2016: 32 · 2015: 29 · 2014: 2
- FWCI
- 26.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (5k12dk094726-05, UL1TR000142)
- National Institute of Diabetes and Digestive and Kidney Diseases (K12-DK094726)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- continuous glucose monitoring, type 1 diabetes, HbA1c, severe hypoglycemia, diabetic ketoacidosis, insulin pump, socioeconomic factors, age differences
- MeSH terms
- Adolescent, Adult, Blood Glucose, Child, Cross-Sectional Studies, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Male, Patient Education as Topic, Registries, Retrospective Studies, Risk Factors, Blood Glucose Self-Monitoring, Incidence, Diabetic Ketoacidosis, Monitoring, Ambulatory, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.